Sunday, June 05, 2022 5:46:39 PM
Bárbara Fernandes,1,2 Rute Castro,1 Farien Bhoelan,3 Denzel Bemelman,3 Ricardo A. Gomes,1 Júlia Costa,2 Patrícia Gomes-Alves,1,2 Toon Stegmann,3 Mario Amacker,4,5 Paula M. Alves,1,2 Sylvain Fleury,4 and António Roldão1,2,*
Wouter L. J. Hinrichs, Academic Editor
Author information Article notes Copyright and License information Disclaimer
1iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal; tp.tebi@sednanrefb (B.F.); tp.tebi@ortsacr (R.C.); tp.tebi@semogar (R.A.G.); tp.tebi@sevlap (P.G.-A.); tp.tebi@seuqram (P.M.A.)
2ITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal; tp.lnu.bqti@atsocj
3Mymetics BV, J.H. Oortweg 21, 2333 CH Leiden, The Netherlands; moc.scitemym@naleohb.neiraf (F.B.); moc.scitemym@namlemeb.lezned (D.B.); moc.scitemym@nnamgets.noot (T.S.)
4Mymetics SA, Route de la Corniche 4, 1066 Epalinges, Switzerland; moc.scitemym@rekcama.oiram (M.A.); moc.scitemym@yruelf.niavlys (S.F.)
5Department of Biomedical Research (DBMR), Department of Pulmonary Medicine, Bern University Hospital, University of Bern, 3008 Bern, Switzerland
*Correspondence: tp.tebi@oadlora; Tel.: +351-214-469-418
In this study, we developed a scalable bioprocess using the insect cells-baculovirus expression vector system (IC-BEVS) to produce high-quality S protein, stabilized in its pre-fusion conformation, for inclusion in a virosome-based COVID-19 vaccine candidate.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031128/
Merck & Co. Licenses Protein Sciences’ Insect Cell Vaccine Production Platform
February 23, 2012
The PS platform uses engineered baculoviruses to generate recombinant proteins in the expresSF+ insect cell line. Protein Sciences claims the platform is fast, low cost, results in correctly folded and biologically active proteins, and is scalable to large volumes and high cell densities. The BEVS technology has already been applied to the development of prophylactic and therapeutic vaccines against infectious viruses, biodefense applications, cancer, and diabetes, as well as rAAV-based gene therapy products for lipid and CNS disorders, and biologics for wound/tissue repair, viral infections, and inflammatory diseases.
https://www.genengnews.com/topics/drug-discovery/merck-co-licenses-protein-sciences-insect-cell-vaccine-production-platform/
Recent MYMX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 06:16:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:00:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 01:53:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:42:46 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 10/17/2023 07:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 10:02:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:01:04 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM